A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Recruiting now

Conditions studied: Locally Advanced Unresectable or Metastatic Gastric Cancer

In brief

This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.

Key facts

Study ID

NCT07547787

Run by

Akeso

People needed

610

Starts

2024-12-26

Expected to finish

2040-12-31

Last updated by the study team

2026-04-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
• Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.
• Agree to proceed with the extended follow-up procedures.
• This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.

You may not qualify if…

• None

Where it is running

• Peking University Cancer Hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.